Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$233.30 USD

233.30
525,994

+4.43 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 114.29% and 1.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Penumbra (PEN) Could Rally 40%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Penumbra (PEN) Q4 Earnings Lag Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of -47.37% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Penumbra (PEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Lags Q3 Earnings Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 10.53% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line

by Zacks Equity Research

Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Penumbra (PEN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 145.45% and 10.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

Until we have nano-bots to cruise our blood vessels, the catheter remains mightier than the scalpel

Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences

by Zacks Equity Research

Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences

Debanjana Dey headshot

5 MedTech Outperformers With Nearly 40% or More Gain in 2021

by Debanjana Dey

Here are a few MedTech stocks, Natus Medical (NTUS), Owens & Minor (OMI), ENDRA Life Sciences (NDRA), Penumbra (PEN), Apollo Medical (AMEH), which might be prudent investment choices now.

John Blank headshot

Strong U.S. Housing Demand: Global Week Ahead

by John Blank

The end of calendar Q1 brings us new Case-Shiller data, a new OPEC+ meeting, and a giant cargo ship still blocking the Suez Canal.

Here's Why You Should Retain Integra LifeSciences (IART) Stock

by Zacks Equity Research

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.